Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma
Susy Shim(Aalborg University Hospital), Morten Ladekarl(Aalborg University Hospital), Jakob B. Sørensen(University of Copenhagen), Per Pfeiffer(University of Southern Denmark), Marianne Nordsmark(Aarhus University Hospital), Anders Christian Larsen(Aalborg University Hospital), Lene Bæksgaard
Cited by 1
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
|JAMA Oncology|2018|518
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|502